Bazal Ganglionların Heredodejeneratif Hastalıkları
Özet
Bazal gangliyonlar, serebellum ve beyin sapını etkileyen heredodejeneratif hastalıklar; metabolik bozukluklar, genetik mutasyonlar ve nörolojik gelişimsel anormallikler temelinde şekillenen geniş ve karmaşık bir klinik spektrumu kapsar. Wilson hastalığı, herediter ataksiler, spastik paraparazi ve çeşitli distoni formları; motor inkoordinasyon, hareket bozuklukları ve bilişsel yıkım gibi ağır semptomlarla kendini gösterir. Tanı aşamasında genetik analizler ve ileri nörogörüntüleme teknikleri belirleyici rol oynarken, tedavide temel yaklaşım semptomatik yönetim ve multidisipliner rehabilitasyon süreçleri üzerine odaklanır. Patolojilerin altında yatan etiyolojik mekanizmaların aydınlatılması, hastaların klinik seyrini ve yaşam kalitesini iyileştirmek için kritik öneme sahiptir.
Heredodegenerative diseases affecting the basal ganglia, cerebellum, and brainstem represent a diverse spectrum of clinical conditions driven by metabolic dysfunctions and underlying genetic mutations. These disorders manifest as complex movement syndromes, ranging from dystonias and parkinsonism to progressive hereditary ataxias and spastic paraplegias, often complicated by cognitive and developmental deficits. Diagnosis primarily depends on detailed genetic profiling and neuroimaging to differentiate specific etiologies, while therapeutic management emphasizes symptom control and multidisciplinary rehabilitative care. Continued research into these molecular pathways remains essential for advancing diagnostic accuracy and optimizing long-term patient care strategies.
Referanslar
Riva D, Taddei M, Bulgheroni S. The neuropsychology of basal ganglia. Vol. 22, European Journal of Paediatric Neurology. W.B. Saunders Ltd; 2018. p.321–6.
Beudel M, Macerollo A, Brown MJN, Chen R. Editorial: The Role of the Basal Ganglia in Somatosensory-Motor Interactions: Evidence From Neurophysiology and Behavior. Vol. 13, Frontiers in Human Neuroscience. Frontiers Media S.A.; 2020.
Aicardi’s Diseases of the Nervous System in Childhood by Alexis Arzimanoglou, Anne O’Hare, Michael V Johnston, Robert Ouvrier (z-lib.org).
Nagral A, Sarma MS, Matthai J, Kukkle PL, Devarbhavi H, Sinha S, et al. Wilson’s Disease: Clinical Practice Guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. Vol. 9, Journal of Clinical and Experimental Hepatology. Elsevier B.V.; 2019. p. 74–98.
Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Vol. 4, Nature Reviews Disease Primers. Nature Publishing Group; 2018.
Svetel M, Potrebić A, Pekmezović T, Tomić A, Kresojević N, Ješić R, et al. Neuropsychiatric aspects of treated Wilson’s disease. Parkinsonism and Related Disorders. 2009 Dec;15(10):772–5.
Fernando M, van Mourik I, Wassmer E, Kelly D. Wilson disease in children and adolescents. Vol. 105, Archives of Disease in Childhood. BMJ Publishing Group; 2020. p. 499–505.
Poujois A, Woimant F. Wilson’s disease: A 2017 update. Vol. 42, Clinics and Research in Hepatology and Gastroenterology. Elsevier Masson SAS; 2018. p.512–20.
Socha P, Janczyk W, Dhawan A, Baumann U, D’Antiga L, Tanner S, et al. Wilson’s Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition. 2018 Feb 1;66(2):334–44.
Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. Vol. 46, Journal of Medical Genetics. 2009. p. 73–80.
Razmeh S, Habibi AH, Orooji M, Alizadeh E, Moradiankokhdan K, Razmeh B. Pantothenate kinase-associated neurodegeneration: Clinical aspects, diangnosis and treatments. Vol. 10, Neurology International. Page Press Publications; 2018. p. 32–4.
Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. Vol. 46, Journal of Medical Genetics. 2009. p. 73–80.
Hogarth P, Kurian MA, Gregory A, Csányi B, Zagustin T, Kmiec T, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Molecular Genetics and Metabolism. 2017 Mar 1;120(3):278–87.
Nlm Citation :, Gregory A, Hayflick S; J, Adam MP, Ardinger HH, Pagon RA. Pantothenate Kinase-Associated Neurodegeneration. 2002.
Sharma LK, Subramanian C, Yun MK, Frank MW, White SW, Rock CO, et al. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications. 2018 Dec 1;9(1).
Hayflick SJ, Kurian MA, Hogarth P. Neurodegeneration with brain iron accumulation. In: Handbook of Clinical Neurology. Elsevier B.V.; 2018. p. 293–305.
Hinarejos I, Machuca-Arellano C, Sancho P, Espinós C. Mitochondrial dysfunction, oxidative stress and neuroinflammation in neurodegeneration with brain iron accumulation (Nbia). Vol. 9, Antioxidants.MDPI; 2020. p. 1–28.
Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ. PLA2G6-Associated Neurodegeneration [Internet]. 2008. Available from: https://www.ncbi.nlm.nih.gov/books/
Iodice A, Spagnoli C, Salerno GG, Frattini D, Bertani G, Bergonzini P, et al. Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: An update for the diagnosis. Vol. 39, Brain and Development. Elsevier B.V.; 2017. p. 93–100.
Nlm Citation :, Gregory A, Venkateswaran S, Hayflick S; J, Adam MP, Ardinger HH, et al. Fatty Acid Hydroxylase-Associated Neurodegeneration. 2011.
Lehéricy S, Roze E, Goizet C, Mochel F. MRI of neurodegeneration with brain iron accumulation. Vol. 33, Current opinion in neurology. NLM (Medline); 2020. p. 462–73.
Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, et al. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN. Vol. 80, Neurology. 2013. p. 268–75.
Gregory A, Klopstock T, Kmiec T, Hogarth P, Hayflick SJ. Mitochondrial Membrane Protein-Associated Neurodegeneration Synonym: Neurodegeneration with Brain Iron Accumulation 4 (NBIA4) [Internet]. 1993. Available from: https://www.ncbi.nlm.nih.gov/books/
Olgiati S, Doğu O, Tufekcioglu Z, Diler Y, Saka E, Gultekin M, et al. The p.Thr11Met mutation in c19orf12 is frequent among adult Turkish patients with MPAN. Parkinsonism and Related Disorders. 2017 Jun 1;39:64–70.
Gregory A, Klopstock T, Kmiec T, Hogarth P, Hayflick SJ. Mitochondrial Membrane Protein-Associated Neurodegeneration Synonym: Neurodegeneration with Brain Iron Accumulation 4 (NBIA4) [Internet].1993. Available from: https://www.ncbi.nlm.nih.gov/books/
Iankova V, Karin I, Klopstock T, Schneider SA. Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders. Vol. 12, Frontiers in Neurology. Frontiers Media S.A.; 2021.
Spaull RVV, Soo AKS, Hogarth P, Hayflick SJ, Kurian MA. Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation. Tremor and Other Hyperkinetic Movements. 2021 Nov 24;11(1).
Tello C, Darling A, Lupo V, Pérez-Dueñas B, Espinós C. On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation. Vol. 93, Clinical Genetics. Blackwell Publishing Ltd;2018. p. 731–40.
Iankova V, Karin I, Klopstock T, Schneider SA. Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders. Vol. 12, Frontiers in Neurology. Frontiers Media S.A.; 2021.
Peters MEM, de Brouwer EJM, Bartstra JW, Mali WPThM, Koek HL, Rozemuller AJM, et al. Mechanisms of calcification in Fahr disease and exposure of potential therapeutic targets. Neurology: Clinical Practice. 2020 Oct;10(5):449–57.
Ooi HW, Er C, Hussain I, Kuthiah N, Meyyur Aravamudan V. Bilateral Basal Ganglia Calcification: Fahr’s Disease. Cureus. 2019 Jun 1;
Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, et al. Mutations in SLC20A2 link familial idiopathic basalganglia calcification with phosphate homeostasis. Nature Genetics. 2012 Mar;44(3):254–6.
Keller A, Westenberger A, Sobrido MJ, García-Murias M, Domingo A, Sears RL, et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nature Genetics. 2013 Sep;45(9):1077–82.
Nicolas G, Pottier C, Maltête D, Coutant S, Rovelet-Lecrux A, Legallic S, et al. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology. 2013 Jan 8;80(2):181–7.
Anheim M, López-Sánchez U, Giovannini D, Richard AC, Touhami J, N’Guyen L, et al. XPR1 mutations are a rare cause of primary familial brain calcification. Journal of Neurology. 2016 Aug 1;263(8):1559–64.
Letort D, Gonzalez-Alegre P. Huntington’s disease in children. In: Handbook of Clinical Neurology. Elsevier B.V.; 2013. p. 1913–7.
Barboza LA, Ghisi NC. Evaluating the current state of the art of huntington disease research: A scientometric analysis. Brazilian Journal of Medical and Biological Research. 2018;51(3).
Sun YM, Zhang Y bin, Wu ZY. Huntington’s Disease: Relationship Between Phenotype and Genotype. Vol. 54, Molecular Neurobiology. Humana PressInc.; 2017. p. 342–8.
Quarrell OWJ, Nance MA, Nopoulos P, Reilmann R, Oosterloo M, Tabrizi SJ, et al. Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease? Vol. 34, Movement Disorders. John Wiley and Sons Inc.; 2019. p. 584–5.
Fusilli C, Migliore S, Mazza T, Consoli F, de Luca A, Barbagallo G, et al. Biological and clinical manifestations of juvenile Huntington’s disease: a retrospective analysis. The Lancet Neurology. 2018 Nov1;17(11):986–93.
van der Knaap MS, Naidu S, Pouwels PJW, Bonavita S, van Coster R, Lagae L, et al. New Syndrome Characterized by Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum.
Joyal KM, Michaud J, van der Knaap MS, Bugiani M, Venkateswaran S. Severe TUBB4A-related hypomyelination with atrophy of the basal ganglia and cerebellum: Novel neuropathological findings. Journal of Neuropathology and Experimental Neurology. 2019 Jan 1;78(1):3–9.
van der Knaap MS, Linnankivi T, Paetau A, Feigenbaum A, Wakusawa K, Haginoya K, et al. Hypomyelination with atrophy of the basal ganglia and cerebellum Follow-up and pathology Supplemental data at www.neurology.org [Internet]. 2007. Available from: www.neurology.org
Hamilton EM, Polder E, Vanderver A, Naidu S, Schiffmann R, Fisher K, et al. Hypomyelination with atrophy of the basal ganglia and cerebellum: Further delineation of the phenotype and genotype-phenotype correlation. Brain. 2014;137(7):1921–30.
Simons C, Wolf NI, McNeil N, Caldovic L, Devaney JM, Takanohashi A, et al. A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. American Journal of Human Genetics. 2013 May 2;92(5):767–73.
Camargo CHF, Camargos ST, Cardoso FEC, Teive HAG. The genetics of the dystonias - A review based on the new classification of the dystonias. Vol. 73, Arquivos de Neuro-Psiquiatria. Associacao Arquivos de Neuro-Psiquiatria; 2015. p. 350–8.
Larsh T, Friedman N, Fernandez H. Child Neurology: Genetically determined dystonias with childhood onset. Neurology. 2020 May 19;94(20):892–5.
Meijer IA, Pearson TS. The Twists of Pediatric Dystonia: Phenomenology, Classification, and Genetics. Seminars in Pediatric Neurology. 2018 Apr 1;25:65–74.
Carbon M, Su ; S, Dhawan ; v, Raymond ; D, Bressman ; S, Eidelberg D. Regional metabolism in primary torsion dystonia Effects of penetrance and genotype. 2004.
Erro R, Klein C. DYT2 revealed: Hippocalcin mutations cause autosomal-recessive isolated dystonia. Vol. 30, Movement Disorders. John Wiley and SonsInc.; 2015. p. 1725.
Wijemanne S, Jankovic J. Dopa-responsive dystonia- Clinical and genetic heterogeneity. Vol. 11, Nature Reviews Neurology. Nature Publishing Group; 2015.p. 414–24.
Çocukluk Çağında distoni [Internet]. 2017. Available from: https://www.researchgate.net/publication/317283203
